BRPI0208411B8 - composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto - Google Patents

composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto

Info

Publication number
BRPI0208411B8
BRPI0208411B8 BRPI0208411A BR0208411A BRPI0208411B8 BR PI0208411 B8 BRPI0208411 B8 BR PI0208411B8 BR PI0208411 A BRPI0208411 A BR PI0208411A BR 0208411 A BR0208411 A BR 0208411A BR PI0208411 B8 BRPI0208411 B8 BR PI0208411B8
Authority
BR
Brazil
Prior art keywords
compound
sexually transmitted
prophylactic
transmitted diseases
pharmaceutical composition
Prior art date
Application number
BRPI0208411A
Other languages
English (en)
Other versions
BR0208411A (pt
BRPI0208411B1 (pt
Inventor
Ross Matthews Barry
Francis O'keefe David
Holan George
Karellas Peter
Andrew Henderson Scott
Original Assignee
Starpharma Ltd
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Ltd, Starpharma Pty Ltd filed Critical Starpharma Ltd
Publication of BR0208411A publication Critical patent/BR0208411A/pt
Publication of BRPI0208411B1 publication Critical patent/BRPI0208411B1/pt
Publication of BRPI0208411B8 publication Critical patent/BRPI0208411B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

"composto, composição farmacêutica tópica e método para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto". uso de um dendrímero de polilisina, poliamidoamina ou polipropilenimina tendo grupos terminais de dissulfonato de naftila como um agente topicamente aplicado na profilaxia ou tratamento de doenças sexualmente transmitidas.
BRPI0208411A 2001-03-30 2002-03-28 composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto BRPI0208411B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR4128A AUPR412801A0 (en) 2001-03-30 2001-03-30 Agent for the prevention and treatment of sexually transmitted disease s - I
PCT/AU2002/000407 WO2002079299A1 (en) 2001-03-30 2002-03-28 Agent for the prevention and treatment of sexually transmitted diseases-i

Publications (3)

Publication Number Publication Date
BR0208411A BR0208411A (pt) 2004-03-30
BRPI0208411B1 BRPI0208411B1 (pt) 2016-06-28
BRPI0208411B8 true BRPI0208411B8 (pt) 2021-05-25

Family

ID=3828128

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208411A BRPI0208411B8 (pt) 2001-03-30 2002-03-28 composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto

Country Status (14)

Country Link
US (2) US7589056B2 (pt)
EP (1) EP1399499B1 (pt)
JP (1) JP4216076B2 (pt)
KR (1) KR100882343B1 (pt)
CN (1) CN1305931C (pt)
AT (1) ATE426001T1 (pt)
AU (2) AUPR412801A0 (pt)
BR (1) BRPI0208411B8 (pt)
CA (1) CA2441357C (pt)
DE (1) DE60231616D1 (pt)
ES (1) ES2324600T3 (pt)
MX (1) MXPA03008909A (pt)
NZ (1) NZ528230A (pt)
WO (1) WO2002079299A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
EP1937284B1 (en) * 2005-10-18 2015-12-02 Starpharma Pty Limited Microbicidal dendrimer composition delivery system
CN104524596B (zh) * 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US8193248B2 (en) 2006-03-22 2012-06-05 Starpharma Pty Limited Contraceptive composition
DK2052011T3 (da) * 2006-08-11 2020-12-07 Starpharma Pty Ltd Målrettet polylysin-dendrimer-terapeutisk stof
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
JP2008202025A (ja) * 2007-01-22 2008-09-04 Honda Motor Co Ltd プロトン伝導性高分子
JP2008270177A (ja) 2007-03-23 2008-11-06 Honda Motor Co Ltd プロトン伝導体
IT1395137B1 (it) 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
US8251452B2 (en) * 2009-11-13 2012-08-28 Hill Jason D Gaming chairs
RS59598B1 (sr) 2011-05-16 2020-01-31 Starpharma Pty Ltd Postupak lečenja ili profilakse bakterijske vaginoze
CN105007910B (zh) 2012-09-13 2019-03-19 星法马有限公司 眼部感染的治疗或预防药物的制造用途
WO2017190193A1 (en) * 2016-05-05 2017-11-09 Starpharma Pty Ltd Method of prophylaxis of zika virus infection
CN110305188B (zh) * 2018-03-23 2020-03-13 广州朗圣药业有限公司 一种预防hiv感染的新化合物及其制备方法
BR112021000658A2 (pt) * 2018-07-19 2021-04-13 Starpharma Pty Ltd Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
EP3930730A4 (en) * 2020-04-15 2022-05-11 Starpharma Pty Limited PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION
CN114053394B (zh) * 2020-07-30 2024-06-21 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
CN114053393B (zh) * 2020-07-30 2024-06-28 广州朗圣药业有限公司 一种药物组合物
CN114053392B (zh) * 2020-07-30 2024-06-21 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗hpv感染的药物中的应用
CN115057911B (zh) * 2022-05-20 2025-01-03 广州朗圣药业有限公司 一种hiv抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
US7572459B2 (en) * 1998-09-14 2009-08-11 Starpharma Pty Ltd. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
AUPP584398A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Inhibition of toxic materials or substances
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
WO2001036328A1 (en) * 1999-11-18 2001-05-25 Exxon Chemical Patents Inc. Method for the synthesis of molecular sieves
US6893506B2 (en) * 2002-03-11 2005-05-17 Micron Technology, Inc. Atomic layer deposition apparatus and method

Also Published As

Publication number Publication date
ATE426001T1 (de) 2009-04-15
US20050008611A1 (en) 2005-01-13
US8158575B2 (en) 2012-04-17
DE60231616D1 (de) 2009-04-30
JP4216076B2 (ja) 2009-01-28
HK1064108A1 (en) 2005-01-21
CA2441357C (en) 2011-05-31
EP1399499A4 (en) 2004-09-29
JP2004532211A (ja) 2004-10-21
CN1503816A (zh) 2004-06-09
EP1399499A1 (en) 2004-03-24
MXPA03008909A (es) 2005-03-07
CN1305931C (zh) 2007-03-21
KR100882343B1 (ko) 2009-02-12
ES2324600T3 (es) 2009-08-11
NZ528230A (en) 2006-02-24
AU2002245932B2 (en) 2007-04-05
US20090269298A1 (en) 2009-10-29
BR0208411A (pt) 2004-03-30
US7589056B2 (en) 2009-09-15
EP1399499B1 (en) 2009-03-18
BRPI0208411B1 (pt) 2016-06-28
KR20040027506A (ko) 2004-04-01
AUPR412801A0 (en) 2001-05-03
WO2002079299A1 (en) 2002-10-10
CA2441357A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
BRPI0208411B8 (pt) composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
SE0100901D0 (sv) New composition
BRPI9908182C1 (pt) composições de proteína de matriz para cura de feridas
EP1609468A3 (en) A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
WO2001041753A3 (en) Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
NO20004282D0 (no) Matriksproteinpreparater for sÕrheling
BR0212576A (pt) Método para o tratamento de distúrbios da pele
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
BR0210428A (pt) Uso de glicoproteìna para preparação de composições para o tratamento e a reepitelização de feridas
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
SE0001916D0 (sv) Novel formulation
ATE405276T1 (de) Pharmazeutische gel-zusammensetzung
BR9801985A (pt) Composição cremosa aplicada na terapeutica da doença de peyronie.
BR0104082A (pt) Processo de tratamento conveniente para a deformação e/ou conformação, e isto de modo permanente, dos materiais queratìnicos e, particulamente, dos cabelos, composição cosmética redutora, e kit para tratamento
BR0317780A (pt) Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas
BR9611033A (pt) Processos para tratar infecção por h.pylori, em um mamífero e para converter a forma coccóide de h. pylori em cultura na forma em espiral e a forma em espiral de h.pylori em cultura na forma coccóide, formulação farmaceutica e uso de um agente capaz de induzir a forma coccóide de h.pylori
PT1347753E (pt) Composicao topica e metodo para o tratamento da incontinencia urinaria de stress
HUP0102164A2 (hu) Hüvelyfertőtlenítő kúp

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: STARPHARMA PTY LTD. (AU)

Free format text: ALTERADO DE: STARPHARMA LIMITED

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28.03.2022.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2716 DE 24/01/2023 POR TER SIDO INDEVIDA.